

30 / 30

Horizons in Healthcare Research

Friday 1st March 2019,
Sydney University



THE UNIVERSITY OF
SYDNEY

 **NHMR C**
Clinical Trials Centre

Program

1.00 – 1.30	Registration and light lunch	
1.30 – 1.35	Welcome and opening <i>A patient's perspective</i>	Julie McCrossin/ Prof Tony Keech
Chairs: Prof Alicia Jenkins & Julie McCrossin		
1.35 – 1.45	Cardio-metabolic: 30 years in 10 minutes	Prof Philip Aylward
1.45 - 1.55	Cancer trials: 30 years in 10 minutes	Prof John Simes
1.55 – 2.05	Neonatal trials: 30 years in 10 minutes	Prof William Tarnow-Mordi
2.05 – 2.15	Return on investment of clinical trials	A/Prof Rachael Morton
2.15 – 2.30	Global reach of Australian trials	Prof Anna Nowak
2.30 – 2.45	The digital future	Prof Jonathan Morris
2.45 – 3.00	Panel discussion	Julie McCrossin
3.00 – 3.30	Afternoon tea	
Chairs: Prof Lisa Askie & Julie McCrossin		
3.30 – 3.45	RCTs in a self-improving health care system	Prof John Zalcberg
3.45 – 4.00	The future of clinical trial funding	Prof Anne Kelso
4.00 – 4.20	Data sharing in clinical trials	Dr Jeff Drazen, MD
4.20 – 4.35	Panel discussion	Julie McCrossin
Chairs: Dr Teresa Anderson & Julie McCrossin		
4.35 – 4.45	Prioritising research - A consumer's perspective	Melinda Cruz
4.45 – 5.00	Molecular & genomic driven trials – Precision medicine	A/Prof Mustafa Khasraw
5.00 – 5.15	Attracting industry trials to Australia	Dr Glenn Begley
5.15 – 5.30	Panel discussion	Julie McCrossin
5.30	Wrap up and close	Prof Tony Keech
5.30 – 7.30	Cocktail Reception, The Refectory Room, Holme Building	




**Dr Teresa
Anderson AM**

Dr Teresa Anderson is the Chief Executive of Sydney Local Health District, one of the leading public health services in Australia. She has more than 35 years of experience as a clinician and health service executive. She has a well-established reputation for implementing strategies to foster innovation and best practice, supporting collaboration and building partnerships.

Teresa is an internationally recognised Speech Pathologist and is passionate about developing programs and services to support and improve the health and wellbeing of all people in the community. In 2018 she was appointed a Member of the Order of Australia (AM).

Dr Anderson is a member of seven Medical Research, Health and PHN boards and is an active member of the Sydney Health Partners Governing Council and Executive Management Group, one of the first four centres in Australia designated by the NHMRC as an Advanced Health Research Translation Centre.

Speaker Biographies



**Professor
Lisa Askie**



Professor Askie leads a team at the CTC, University of Sydney, which manages the Australian New Zealand Clinical Trials Registry, undertakes Health Technology Assessments for the Australian Federal Government, hosts two Cochrane Collaboration entities (Breast Cancer Review Group, Prospective Meta-analysis Methods Group) and has an extensive test evaluation research program.

Lisa's clinical background is in perinatal medicine and she has worked in healthcare systems in Asia, Australia, UK and USA. She has Masters and Doctoral qualifications in epidemiology from Sydney Medical School, is a Senior Principal Research Fellow at the University of Sydney and has held an NHMRC Postgraduate Scholarship, a Sidney Sax Postdoctoral Fellowship, a Career Development Fellowship and currently, a Translating Research Into Practice (TRIP) Fellowship.

**Professor
Philip Aylward**



Professor Aylward is Professor of Medicine at Flinders University and the Director of Strategic Relationships within the Southern Adelaide Local Health Network. He is a Member of the Innovation Centre within SAHMRI Heart Health and leads the development of Education Programmes.

Philip is a Cardiologist with over two decades of involvement in clinical trials. He has been a National Co-ordinator and member of a number of international steering and executive committees in cardiology, particularly in acute coronary syndromes, lipid management, atrial fibrillation and heart failure.

Philip was Co-chair and author of the initial Australian Guidelines for the Management of Acute Coronary Syndromes 2006 and was a Member of the 2017 Acute Coronary Syndrome Guidelines Writing Committee of the National Heart Foundation and Cardiac Society of Australia & New Zealand.

**Dr C. Glenn
Begley**



Dr C. Glenn Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities, created to provide commercial focus in the early phases of drug development.

Glenn served as Chief Scientific Officer at Akrieva Therapeutics, California (2016–2017) and TetraLogic Pharmaceuticals, Pennsylvania (2012–2016). From 2002–2012, he was Vice-President and Global Head of Haematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen's five research sites.

Before Amgen, Glenn had over 20 years of clinical experience in medical oncology and haematology. His personal research focused on regulation of haematopoietic cells and translational clinical trials. His early studies first described human G-CSF, and in later clinical studies, first demonstrated that G-CSF-mobilised blood stem cells hastened haematopoietic recovery. This finding revolutionised the clinical approach to bone marrow transplantation.

Glenn's honours include being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, to the Association of American Physicians in 2008, to the Research 'Hall of Fame' at his alma mater, the Royal Melbourne Hospital, in 2014, and to the Australian Academy of Health and Medical Sciences in 2016.

**Melinda
Cruz**



Melinda Cruz is the mother of three babies born prematurely and is the award-winning Founder of Miracle Babies Foundation, Australia's largest and leading neonatal consumer group. Melinda was appointed as an Honorary Research Associate at the CTC, and was the first parent to be an Associate Investigator on a CTC neonatal trial, LIFT.

Melinda is a trusted consumer expert to medical professionals seeking to improve treatments and understanding of premature and sick babies and the impact a birth has on the family unit. In 2014, Melinda joined the PSANZ Consumer Advisory Panel and accepted a position on the PSANZ Clinical Trials executive committee. In 2016, she was asked to join the NHMRC Clinical Trials Ready Development Committee and contributed to the dissemination of the results of BOOST II and APTS trials. In 2015, she joined the Australian Red Cross Blood Service Milk Bank Advisory Committee.

Under Melinda's leadership, Miracle Babies Foundation has established a major impact and reach, with almost 60,000 likes on Facebook and an active and engaged audience on Twitter, Instagram and LinkedIn. Melinda was recently invited to become a regular contributor to THRIVE Global, an international portal for health and wellbeing, in which she has published five articles to date.

She is currently working on publishing her first book.

**Dr Jeff
Drazen**



Dr Jeff Drazen joined the New England Journal of Medicine (NEJM) as Editor-in-Chief in July of 2000. In 2012, he was appointed Editor-in-Chief of NEJM Group, which also publishes NEJM Journal Watch, NEJM Knowledge+, NEJM Catalyst, NEJM Resident 360, and NEJM Yi Xue Qian Yan.

A specialist in pulmonology, Jeff maintains an active research program. He has published more than 300 articles on topics such as lung physiology and the mechanisms involved in asthma. Throughout his distinguished career, he has served many academic and hospital appointments and received numerous honours.

Jeff is the Distinguished Parker B. Francis Professor of Medicine at Harvard Medical School, Professor of Physiology at the Harvard School of Public Health, and a senior physician at Brigham and Women's Hospital. In 2003, he was elected as a member of both the Institute of Medicine and the Royal Society of Medicine. Jeff has served on numerous committees for the National Institutes of Health.

Jeff earned his bachelor's degree and graduated *summa cum laude* from Tufts University. He received his medical degree from Harvard Medical School and completed his internship and residency at Peter Bent Brigham Hospital in Boston. Jeff was a clinical and a research fellow at both Harvard Medical School and the Harvard School of Public Health.

**Professor
Alicia Jenkins**



Alicia Jenkins is a Professor of Diabetes and Vascular Medicine at the CTC. She has collaborated with the CTC since 2000 and she and her team moved to the CTC in 2012 / 13. She trained at the University of Melbourne (Australia), in Ireland, the UK, and the US. She is an endocrinologist with clinical and research interests in diabetes and its complications, including the use of technology in diabetes care, as well as insulin pumps, glucose sensors and telehealth. With over 25 years of research experience Alicia leads clinical and basic science research exploring diabetes and its complications, clinical, biochemical and molecular biomarkers, and trials, including the FIELD, T4DM, DCCT/EDIC, REMOVAL, FAME-1 trials and insulin pump studies. Alicia has over 350 publications and mentors a wide range of clinician researchers. She holds a NHMRC Practitioner Fellowship, she has served on the Australian Diabetes Society Council, is on the IDF Western Pacific Region Executive Council and is President of the Insulin for Life (global and Australia) diabetes charity. She and her team have extensive national and international collaborations.

**Professor
Tony Keech**



Professor Tony Keech is Senior Principal Research Fellow and Deputy Director of the CTC. He co-leads the research team at the CTC and for the last ten years has chaired the CTC's Research Committee.

Tony is Professor of Medicine, Cardiology and Epidemiology at the University of Sydney, an internationally renowned researcher in the field of cardiovascular clinical trials, and Chair and Principal Investigator of the FIELD diabetes study. His research has influenced health outcomes, particularly in treatments of acute myocardial infarction, cardiovascular disease prevention of chronic heart disease, and diabetes and its vascular complications. He is recognised internationally for collaborative research into coronary risk factors, treatments for acute coronary syndromes, prediction of vascular disease, and treatment and diabetes complication prevention.

Tony is a founding member of the Board of Directors, Australian Clinical Trials Alliance (ACTA), formed in 2012 to promote effective and evidence-based healthcare in Australia through investigator-initiated clinical trials. He is a consultant cardiologist at Royal Prince Alfred Hospital and continues to teach students and postgraduates in medicine, public health and epidemiology.

**Professor
Anne Kelso**



Professor Anne Kelso AO is the Chief Executive Officer of the NHMRC. Following her PhD at the University of Melbourne, Anne undertook research in the field of immunology, first in Switzerland and then at the Walter and Eliza Hall Institute of Medical Research in Melbourne and the Queensland Institute of Medical Research in Brisbane.

From 2000 until 2006, Anne was also Director/CEO of the Cooperative Research Centre for Vaccine Technology. She then returned to Melbourne as Director of the WHO Collaborating Centre for Reference and Research on Influenza from 2007 until she took up her role with NHMRC in April 2015.

Anne is a current member of several government and international committees, including the Australian Medical Research Advisory Board (advising the Minister for Health on the strategy and priorities for the Medical Research Future Fund), the Board of the Global Alliance for Chronic Diseases and the Human Frontier Science Program Organization.

Anne was elected a fellow of the Australian Academy of Science and the Australian Academy of Health and Medical Sciences in 2018.

**Associate
Professor
Mustafa
Khasraw**



Associate Professor Mustafa Khasraw is a Clinical Lead at the CTC with a leading role in several clinical and translational programs. He is also a practising medical oncologist at Royal North Shore Hospital in Sydney.

Mustafa has worked in several countries and received his MD from the University of Groningen in the Netherlands. He worked as an oncology fellow at Addenbrooke's Hospital in Cambridge from 2005 to 2007, and then began training as a medical oncologist at Royal North Shore Hospital in Sydney. In 2011, he completed a subsequent fellowship at Memorial Sloan-Kettering Cancer Center in New York before returning to Australia.

Mustafa has worked at the CTC since 2012. He leads an extensive clinical trials team with significant laboratory collaborations focusing on targeted therapies and immuno-oncology in glioblastoma and other underserved cancers. He is lead Principal Investigator on Phase I, II and III clinical trials for a number of ongoing academic and pharmaceutical multi-centre clinical studies with a special interest in innovative trial design. Mustafa holds a Medical Research Future Fund Next Generation Clinical Trials Fellowship.

**Julie
McCrossin AM**



Julie McCrossin gets people talking. After 20 years as a broadcaster with ABC Radio National, ABC TV and Network Ten, she is now a freelance journalist and broadcaster. Julie writes for the NSW Law Society Journal and LOTL Magazine and facilitates conferences and seminars. Julie has qualifications in the arts, education and law. After treatment for stage 4 throat cancer in 2013, Julie is now an Ambassador for Beyond Five, Targeting Cancer and TROG Cancer Research. Julie hosts the podcast series, The Thing About Cancer for Cancer Council NSW. In 2019 Julie received an AM for service to the community, particularly advocacy for LGBTI people and the media. www.juliemccrossin.com

**Professor
Jonathan
Morris**



Professor Jonathan Morris is a graduate of the University of Edinburgh and completed his Obstetric and Maternal Fetal Medicine sub specialty training in Sydney. He completed his PhD in Oxford and returned to Sydney in 1998 to the Royal North Shore Hospital. Since then he has built a perinatal research group that extends from basic science to population health. His major research interests are the prediction, prevention and management of pregnancy complications, which have led to a number of large clinical trials that have informed practice in Australia and overseas.

**Associate
Professor
Rachael
Morton**



Associate Professor Rachael Morton is Director of Health Economics at the CTC and an NHMRC TRIP Fellow. She has a MScMed (Clin Epi)(Hons) and a PhD in Health Economics from the University of Sydney. She spent two years working at the Health Economics Research Centre, University of Oxford as part of her NHMRC Sidney Sax Postdoctoral Fellowship.

Rachael specialises in trial-based and modelled economic evaluation, and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.

Rachael is co-chair of the ACTA Research Prioritisation working group, and President of the Health Services Research Association of Australia and New Zealand (HSRAANZ). She is a member of the Science in Australia Gender Equity (SAGE) team at the University of Sydney, and Chair of its Data Working Group.

Rachael coordinates short courses in health economics for government and industry and currently supervises five PhD candidates. She has published 120 articles in applied health economics and health services research.

**Professor
Anna Nowak**



Professor Anna Nowak is a Medical Oncologist at Sir Charles Gairdner Hospital (SCGH) and Professor within the School of Medicine, University of Western Australia, with longstanding research and clinical interests in malignant mesothelioma and neuro-oncology.

Anna is the current Chair of COGNO (CoOperative Group for Neuro-Oncology) and the Director of the National Research Centre for Asbestos Related Diseases (NCARD), an NHMRC Centre for Research Excellence.

After a laboratory-based PhD in tumour immunology Anna was the inaugural postdoctoral clinical trials fellow at the CTC. She has been Principal Investigator for a number of local and national clinical trials, including most recently the ALTG DREAM study, and is an active member of COGNO and ALTG trial management committees.

Anna also has interests in quality of life, imaging, staging, and tumour measurement, and maintains a translational research laboratory.

**Professor
John Simes**



Professor John Simes is Senior Principal Research Fellow, Founder and Director of the CTC.

He is a leading international researcher in clinical trials, particularly in cancer, cardiovascular disease, diabetes and neonatal medicine. He has contributed to over 300 peer-reviewed articles, with many having a significant impact on current knowledge and clinical practice.

John was the Founding Director of Sydney Catalyst Translational Cancer Research Centre, a virtual centre of cancer researchers in central Sydney and regional NSW. He is a founding member of the Board of Directors of the ACTA, formed in 2012 to promote effective and evidence-based healthcare in Australia through investigator-initiated clinical trials.

John is a practising medical oncologist in neuro-oncology at Royal Prince Alfred Hospital and the Chris O'Brien Lifehouse, and is Professor of Clinical Epidemiology at Sydney Medical School, University of Sydney.

His research has been recognised in a number of awards including the NSW Premier's Award for Outstanding Cancer Research (2016), the Alan Coates Award for Excellence in Clinical Trials Research (2016), the Harvard Alum Award (Biostatistics) (2009), the MOGA Cancer Achievement Award (2010) and the Vice-Chancellor's Award for Outstanding Research (2017, University of Sydney). He was named on the Clarivate Analytics World's Highly Cited Researchers List for 2018.

**Professor
William
Tarnow-Mordi**



Professor William Tarnow-Mordi is Director of Neonatal and Perinatal Trials at the CTC and Foundation Director of the WINNER Centre for Newborn Research at the University of Sydney.

William completed his medical training at the University of Cambridge, UK, followed by specialist training in Paediatrics and Neonatal Medicine. He migrated to Australia in 1999 to commence an appointment as inaugural Professor of Neonatal Medicine, University of Sydney and as Director of Neonatology, Westmead Hospital, where he led NSW's busiest neonatal department until 2010.

Trials in extremely premature babies are challenging, and William and his team work to form global partnerships to find cost-effective treatments that will reduce infant mortality and illness. The CTC's Neonatal Research program focuses on areas of need, such as neonatal infection, oxygen therapy and simple cost-effective measures to reduce health problems and improve outcomes for high-risk newborn infants.

William's work has helped to improve survival rates in very preterm infants, influence clinical practice and achieve major health care cost savings worldwide by identifying ineffective treatments. He serves on the Steering Group of NSW Health's Better Treatment for Kids Network and is co-chair of the Perinatal Society of Australia and New Zealand Clinical Trials Working Group.

**Professor
John Zalcborg**



Professor John Zalcborg was the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne, Australia for 17 years prior to recently taking up the position of Head, Cancer Research Program in the School of Public Health and Preventive Medicine within the Faculty of Medicine, Nursing and Health Sciences at Monash University. After earning a Bachelor of Medicine and Bachelor of Surgery from the University of Melbourne and a PhD in cancer immunology, John served as Director of Medical Oncology at the Heidelberg Repatriation Hospital and as Director of Cancer Services at the Austin and Repatriation Medical Centre.

John has over 250 articles published in peer-reviewed journals. A founder of the Lorne Cancer Conference and the Australasian Gastrointestinal Trials Group (AGITG), he is immediate past Chair of the Board of AGITG after serving in this role for over 15 years and a past Board Member of Cancer Trials Australia. John is the current Co-Chair of the Cancer Drugs Alliance and Chair of ACTA. He also serves on the Board of the Australian Red Cross Blood Service.

John has received a Medal of the Order of Australia Award (OAM), the 2011 Cancer Achievement Award from the Medical Oncology Group of Australia and the 2015 Tom Reeve Award for outstanding contribution to cancer care from the Clinical Oncological Society of Australia (COSA).

In 2014 the AGITG announced the annual 'John Zalcborg OAM Award for Excellence in AGITG Research' in his honour.



Celebrating
30
years